Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) FCF Margin: 2011-2025

Historic FCF Margin for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -3,074.84%.

  • Abeona Therapeutics' FCF Margin rose 1145160.00% to -3,074.84% in Q3 2025 from the same period last year, while for Sep 2025 it was -5,783.71%, marking a year-over-year increase of 113394.00%. This contributed to the annual value of -153,844.74% for FY2024, which is 15277788.00% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' FCF Margin is -3,074.84%, which was up 43.28% from -5,421.25% recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' FCF Margin peaked at 69,802.08% during Q4 2021, and registered a low of -20,613.24% during Q4 2022.
  • For the 3-year period, Abeona Therapeutics' FCF Margin averaged around -456.54%, with its median value being -3,074.84% (2025).
  • In the last 5 years, Abeona Therapeutics' FCF Margin soared by 6,985,685bps in 2021 and then crashed by 9,041,532bps in 2022.
  • Over the past 5 years, Abeona Therapeutics' FCF Margin (Quarterly) stood at 69,802.08% in 2021, then crashed by 9,041,532bps to -20,613.24% in 2022, then soared by 1,915,077bps to -1,462.46% in 2023, then skyrocketed by 3,055,568bps to 29,093.22% in 2024, then spiked by 1,145,160bps to -3,074.84% in 2025.
  • Its FCF Margin was -3,074.84% in Q3 2025, compared to -5,421.25% in Q2 2025 and -6,347.12% in Q1 2025.